These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25335522)

  • 41. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
    Gründer G
    Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Inclusion - pediatric and adolescent psychiatry aspects].
    Warnke A
    Z Kinder Jugendpsychiatr Psychother; 2015 Jul; 43(4):231-42. PubMed ID: 26118811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers.
    Spetie L; Arnold LE
    Psychopharmacology (Berl); 2007 Mar; 191(1):15-26. PubMed ID: 17279378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
    Riedel C; Lehmann B; Broich K; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
    Barbui C; Cipriani A; Lintas C; Bertelé V; Garattini S
    Psychopharmacology (Berl); 2007 Feb; 190(2):265-8. PubMed ID: 17119928
    [No Abstract]   [Full Text] [Related]  

  • 49. [Nonnative guidelines for allocating human resources in child and adolescent psychiatry using average values under convergence conditions instead of price determination - analysis of the data of university hospitals in Germany concerning the costs of calculating day and minute values according to Psych-PV and PEPP-System].
    Barufka S; Heller M; Prayon V; Fegert JM
    Z Kinder Jugendpsychiatr Psychother; 2015 Nov; 43(6):397-409. PubMed ID: 26602045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The new German reimbursement system for psychiatric hospitals as a "learning system"].
    Schepker R; Fegert JM
    Z Kinder Jugendpsychiatr Psychother; 2013 May; 41(3):159-62. PubMed ID: 23639923
    [No Abstract]   [Full Text] [Related]  

  • 51. Collaborative psychiatric consultations: Guidance for primary care providers who prescribe psychotropic medications for children.
    Reinke MB; Edwall G; Nygaard P; Zakelj J
    Minn Med; 2011 Oct; 94(10):57-9. PubMed ID: 23256288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research in child and adolescent psychopharmacology: recent accomplishments and new challenges.
    Vitiello B
    Psychopharmacology (Berl); 2007 Mar; 191(1):5-13. PubMed ID: 16718480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry].
    Hebebrand J; Blanz B; Herpertz-Dahlmann B; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):133-8. PubMed ID: 22774235
    [No Abstract]   [Full Text] [Related]  

  • 54. Increasing use of psychotropic medications in children and adolescents: what does it mean?
    Walkup JT
    J Child Adolesc Psychopharmacol; 2003; 13(1):1-3. PubMed ID: 12812148
    [No Abstract]   [Full Text] [Related]  

  • 55. [Legal decisions of german supreme courts about prescription of drugs for not registered indications ("off-label-use")].
    Wetterling T
    Fortschr Neurol Psychiatr; 2004 May; 72(5):255-9. PubMed ID: 15136946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pediatric psychopharmacology.
    Simeon JG
    Can J Psychiatry; 1989 Mar; 34(2):115-22. PubMed ID: 2650855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Not Available].
    Schepker R; Freitag C; Kölch M; Romanos M
    Z Kinder Jugendpsychiatr Psychother; 2018 Sep; 46(5):447-450. PubMed ID: 30204072
    [No Abstract]   [Full Text] [Related]  

  • 58. [Psychopharmacology and psychotherapy in pediatric oncology. Update and perspectives of integration].
    Clerici CA; Giacon B; Polastri D; Simonetti F; Veneroni L; Ferrari A; Massimino M
    Recenti Prog Med; 2011; 102(7-8):314-20. PubMed ID: 21779126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
    Barbui C; Garattini S
    Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.
    Sharav VH
    Ethical Hum Sci Serv; 2003; 5(2):83-108. PubMed ID: 15279010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.